Form 4: Intellia Director Brian Goff Receives Equity Grant

Intellia Therapeutics director Brian Goff was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Summary

• Director Brian Goff received a grant of 9,200 restricted stock units (RSUs) representing a contingent right to receive common stock.
• Director Brian Goff was granted 13,300 stock options with an exercise price of $12.89 per share.
• The stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.
• Following these transactions, the reporting person beneficially owns 32,609 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The issuance of equity grants results in potential future dilution for existing shareholders.

Risks

• Market volatility may impact the value of the granted equity instruments.
• The value of the stock options is dependent on the future performance of the company's common stock price relative to the $12.89 exercise price.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term retention and alignment with shareholder value creation.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common industry practice for non-employee directors.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the stock options on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Equity Grant, Director Compensation